Last mentioned: Mar 16, 2026
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Public Criticism
Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem.
Market Impact
Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty.
Industry Warning
Editorials warn that erratic FDA behavior is a threat to biotech innovation.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Regulatory U-Turn
The FDA officially agrees to consider the application after resolving the internal and public dispute.
Public Dispute
Reports emerge that career FDA scientists were overruled, leading to a public standoff between Moderna and the agency.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
Initial Rejection
Trump administration vaccine chief refuses to review Moderna's mRNA flu shot application.
Refusal to File
FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application.
Refusal to File
Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns.
Refusal to File
Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application.
Refusal to File
FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application.
Application Refusal
FDA senior regulator Vinay Prasad issues a formal refusal to review the flu vaccine application.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
Grants Rescinded
The administration pulls back hundreds of millions in funding for mRNA-based research projects.
Grants Rescinded
White House rescinds hundreds of millions in mRNA research grants by year-end.
Grants Rescinded
The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts.
Moderna faces a significant regulatory setback as the FDA refuses to review its new flu vaccine, citing trial design flaws despite previous guidance. This shift reflects a broader, politically charged environment that threatens to destabilize the venture-backed biotech ecosystem.
Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment.
Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight.
The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response.
The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms.
The FDA has agreed to review Moderna’s mRNA-based influenza vaccine after a high-profile rejection by the Trump administration's vaccine chief. The reversal follows a public dispute where scientific staff were reportedly overruled, marking a significant shift for the first-of-its-kind vaccine candidate.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.